GenoGenix LLC
Has GenoGenix LLC received an FDA warning letter? Yes. FDA issued a warning letter dated January 20, 2026.
Letter facts
- Letter date
- January 20, 2026 (2026-01-20)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Compounding Pharmacy
- Products named
- Glutathione MagnesiumReconstitution SolutionEpithalonRapamycinClear Mind 150LIPO (MIC) + BAscorbic Acid Vitamin CAlpha Lipoic AcidImmune Defense Nasal Sprayinjectable methylcobalamin 5,000 mcg/mLinjectable B Complex
- Violation categories
- Compounding outside 503A/503BCGMP / insanitary conditions
Understanding these violation categories
Compounding outside 503A/503B
FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA says sterile drug products compounded with ineligible bulk substances and deficient labeling; produced under insanitary conditions without media fills, environmental monitoring, or airflow validation; CGMP failures; released products with strength below label claim.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Failure to meet section 503B conditions (ineligible bulk drug substances, labeling, registration/reporting, adverse event reporting)
- Adulteration due to insanitary conditions (FDCA 501(a)(2)(A))
- CGMP violations (FDCA 501(a)(2)(B))
- Adulteration due to strength failing label claim (FDCA 501(c))
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Compounding outside 503A/503B)
Recent warning letters with related regulatory findings:
- Empower PharmacySeptember 18, 2026
- ProRx LLCApril 7, 2026
- Apothecary Pharma, LLCDecember 1, 2025
- PQ Pharmacy, LLCOctober 10, 2025
- Amazing MedsSeptember 9, 2025
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.